AVITA Medical (RCEL) Research & Development (2018 - 2025)

AVITA Medical has reported Research & Development for 8 years, with the latest figure at $5.7 million in Q4 2025.

• For the quarter ending Q4 2025, Research & Development rose 17.34% year-over-year to $5.7 million; the trailing twelve-month figure through Dec 2025 stood at $20.8 million (up 2.36% YoY), and the FY2025 full-year result was $20.8 million, up 2.35% from the prior year.
• Research & Development for Q4 2025 stood at $5.7 million, up from $3.7 million in the prior quarter.
• The five-year high for Research & Development was $6.8 million in Q4 2023, with the low at $3.4 million in Q4 2022.
• Historically, Research & Development has averaged $4.7 million across 5 years, with a median of $4.7 million in 2023.
• Annual changes were most pronounced in 2023 — Research & Development jumped 100.21% — and 2025, when it tumbled 30.95%.
• AVITA Medical's Research & Development stood at $3.4 million in 2021, then retreated by 0.27% to $3.4 million in 2022, then surged by 100.21% to $6.8 million in 2023, then slipped by 28.31% to $4.8 million in 2024, then advanced by 17.34% to $5.7 million in 2025.
• The last three Research & Development figures came in at $5.7 million (Q4 2025), $3.7 million (Q3 2025), and $5.1 million (Q2 2025), per Business Quant data.